Connect with us

Hi, what are you looking for?

OTC Markets:RHHBY

Roche to present new OCREVUS (ocrelizumab) data in multiple

#Roche #present #OCREVUS #ocrelizumab #data #multiple

  • OCREVUS data will show significant benefit on slowing disease activity and progression in patients with treatment-naive early-stage relapsing-remitting multiple sclerosis (RRMS)
  • Largest pregnancy safety data across anti-CD20 medicines for OCREVUS in multiple sclerosis (MS)
  • Nine-year safety data for OCREVUS reinforces its favourable benefit-risk profile
  • New research demonstrates impact of misdiagnosis and delay of starting treatment in NMOSD

Basel, 19 October 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) data and continued research into neuromyelitis optica spectrum disorder (NMOSD) will be presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 26-28 October 2022. These data include 35 abstracts, highlighting disease activity and progression results in early-stage RRMS, pregnancy outcomes from more than 2,000 women with MS and long-term safety data for OCREVUS, as well as global NMOSD data exploring impact of delayed treatment, clinical characterization of disease severity and stability, and accurate identification of people living with NMOSD through healthcare claims-based algorithms. Finally, the design of a Phase III study evaluating the efficacy and safety of satralizumab in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD), a rare, chronic and debilitating autoimmune disease primarily affecting the optic nerve, brain and spinal cord, will be presented.

“Our aim is to enable people living with MS and NMOSD to maintain life to the fullest. With over 250,000 people treated with OCREVUS, we continue to see significant reductions in MS disease progression balanced with favourable safety,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We are also focused on remaining unmet needs – such as earlier diagnosis and treatment – which is critical to ensure patients are…

Read on GNW: Roche to present new OCREVUS (ocrelizumab) data in multiple

You May Also Like

press release

With a deep understanding of the latest tech, Erbo helps businesses flourish in a digital world.

Business

State would join dozens of others in enacting legislation based on federal government’s landmark whistleblower statute, the False Claims Act

Health News

The cosmetic and facial plastic surgery practice is hosting a grand opening celebration and ribbon cutting for its new Chattanooga state-of-the-art location.

press release

#Automotive #Carbon #Canister #Market #Projected #Hit #USD New York, US, Oct. 24, 2022 (GLOBE NEWSWIRE) —  According to a comprehensive research report by Market...